Diabetic nephropathy (DN) is one of the most common complications of Type-2 diabetes, which has become a leading cause of death in patients with end-stage renal disease1,2 as well as in those with diabetes.3,4 It is suggested that DN is affected by numerous factors such as glomerular hemodynamic alterations, activated renin-angiotensin-aldosterone system (RAAS), lipid metabolism disorders, and increased cytokines, which underpins the need for new therapeutic approaches to prevent and slow the progress of DN. Here, REN is linked to liver dysplastic nodule.